Researchers open the way to new treatments for chronic pain and cancer

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2). Taken in addition to their study of its molecular mechanism last year, Dr. Vera Moiseenkova-Bell’s laboratory has revealed TRPV2 as new target for pharmaceutical research treating chronic pain and cancer.
Go to Source